

Rafael Tabares-Seisdedos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2916704/publications.pdf>

Version: 2024-02-01

196
papers

80,071
citations

11235

73
h-index

2970

195
g-index

205
all docs

205
docs citations

205
times ranked

105435
citing authors

#	ARTICLE	IF	CITATIONS
1	Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study. <i>Journal of Affective Disorders</i> , 2022, 300, 99-108.	2.0	3
2	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. <i>Lancet Public Health</i> , The, 2022, 7, e105-e125.	4.7	1,199
3	Burden of non-communicable diseases among adolescents aged 10â€“24 years in the EU, 1990â€“2019: a systematic analysis of the Global Burden of Diseases Study 2019. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 367-383.	2.7	48
4	Specific metabolic syndrome components predict cognition and social functioning in people with type 2 diabetes mellitus and severe mental disorders. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 215-226.	2.2	7
5	Mortality in Persons With Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder. <i>JAMA Pediatrics</i> , 2022, 176, e216401.	3.3	44
6	The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990â€“2019: Findings from the Global Burden of Disease Study 2019. <i>Lancet Regional Health - Europe</i> , The, 2022, 16, 100341.	3.0	70
7	Design and methodological characteristics of studies using observational routinely collected health data for investigating the link between cancer and neurodegenerative diseases: protocol for a meta-research study. <i>BMJ Open</i> , 2022, 12, e058738.	0.8	1
8	Immuneâ€“Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A 1-Year Follow-Up Study. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	4
9	Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from Vigibase. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1513-1521.	0.8	3
10	Possible Ancestral Functions of the Genetic and RNA Operational Precodes and the Origin of the Genetic System. <i>Origins of Life and Evolution of Biospheres</i> , 2021, 51, 167-183.	0.8	2
11	Transcriptomic and Genetic Associations between Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Cancer. <i>Cancers</i> , 2021, 13, 2990.	1.7	26
12	Lifestyle in Undergraduate Students and Demographically Matched Controls during the COVID-19 Pandemic in Spain. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8133.	1.2	7
13	Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 241.	1.5	2
14	Is processing speed a valid neurocognitive endophenotype in bipolar disorder? Evidence from a longitudinal, family study. <i>Journal of Psychiatric Research</i> , 2021, 141, 241-247.	1.5	10
15	Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1030-1049.	5.2	86
16	Global, regional, and national burden of bone fractures in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>The Lancet Healthy Longevity</i> , 2021, 2, e580-e592.	2.0	277
17	Lifestyle changes and mental health during the COVID-19 pandemic: A repeated, cross-sectional web survey. <i>Journal of Affective Disorders</i> , 2021, 295, 173-182.	2.0	32
18	Mapping child growth failure across low- and middle-income countries. <i>Nature</i> , 2020, 577, 231-234.	13.7	128

#	ARTICLE	IF	CITATIONS
19	Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis. <i>BMJ Open</i> , 2020, 10, e034463.	0.8	27
20	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	6.3	7,664
21	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	6.3	3,928
22	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
23	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	6.3	335
24	Motor and Cognitive Performance in Patients with Liver Cirrhosis with Minimal Hepatic Encephalopathy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2154.	1.0	13
25	Grip Strength, Neurocognition, and Social Functioning in People With Type-2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia. <i>Frontiers in Psychology</i> , 2020, 11, 525231.	1.1	9
26	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	2.9	23
27	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. <i>Injury Prevention</i> , 2020, 26, i125-i153.	1.2	44
28	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1250-1284.	6.3	330
29	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. <i>The Lancet Global Health</i> , 2020, 8, e1162-e1185.	2.9	91
30	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i96-i114.	1.2	103
31	Childhood trauma and substance use underlying psychosis: a systematic review. <i>HÅrgre Utbildning</i> , 2020, 11, 1748342.	1.4	17
32	Interpreting molecular similarity between patients as a determinant of disease comorbidity relationships. <i>Nature Communications</i> , 2020, 11, 2854.	5.8	20
33	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. <i>Trials</i> , 2020, 21, 34.	0.7	19
34	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet, The</i> , 2020, 396, 693-724.	6.3	87
35	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	1.2	44
36	Morbidity and mortality from road injuries: results from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i46-i56.	1.2	86

#	ARTICLE	IF	CITATIONS
37	Peripheral Oxidative Stress Markers in Patients with Bipolar Disorder during Euthymia and in Siblings. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 77-86.	0.6	9
38	Visual memory dysfunction as a neurocognitive endophenotype in bipolar disorder patients and their unaffected relatives. Evidence from a 5-year follow-up Valencia study.. <i>Journal of Affective Disorders</i> , 2019, 257, 31-37.	2.0	12
39	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. <i>Lancet Oncology</i> , The, 2019, 20, 1211-1225.	5.1	199
40	Neurocognitive endophenotypes in schizophrenia and bipolar disorder: A systematic review of longitudinal family studies. <i>Schizophrenia Research</i> , 2019, 210, 21-29.	1.1	23
41	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 913-933.	3.7	259
42	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. <i>Nature</i> , 2019, 574, 353-358.	13.7	161
43	Cataracts and statins. A disproportionality analysis using data from VigiBase. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 109, 104509.	1.3	4
44	The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 934-947.	3.7	372
45	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. <i>JAMA Oncology</i> , 2019, 5, 1749.	3.4	1,691
46	Association of Anorexia Nervosa With Risk of Cancer. <i>JAMA Network Open</i> , 2019, 2, e195313.	2.8	10
47	Prevalence and comorbidity of autism spectrum disorder in Spain: study protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , 2019, 8, 141.	2.5	10
48	Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995â€“2050. <i>Lancet</i> , The, 2019, 393, 2233-2260.	6.3	283
49	Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. <i>Molecular Autism</i> , 2019, 10, 17.	2.6	30
50	Reporting guidelines for health research: protocol for a cross-sectional analysis of the EQUATOR Network Library. <i>BMJ Open</i> , 2019, 9, e022769.	0.8	10
51	CIBERSAM: Ten years of collaborative translational research in mental disorders. <i>Revista De PsiquiatrÃa Y Salud Mental (English Edition)</i> , 2019, 12, 1-8.	0.2	5
52	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 459-480.	4.9	2,625
53	Global, regional, and national burden of brain and other CNS cancer, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 376-393.	4.9	359
54	Prevalence and comorbidity of attention deficit hyperactivity disorder in Spain: study protocol for extending a systematic review with updated meta-analysis of observational studies. <i>Systematic Reviews</i> , 2019, 8, 49.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Global, regional, and national burden of epilepsy, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 357-375.	4.9	526
56	Subjective neurocognition and quality of life in patients with bipolar disorder and siblings. <i>Journal of Affective Disorders</i> , 2019, 245, 283-288.	2.0	21
57	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 88-106.	4.9	1,512
58	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 56-87.	4.9	1,064
59	Diez aÃ±os de investigaci3n traslacional colaborativa en enfermedades mentales: el CIBERSAM. <i>Revista De PsiquiatrAa Y Salud Mental</i> , 2019, 12, 1-8.	1.0	68
60	The Burden of Cardiovascular Diseases Among US States, 1990-2016. <i>JAMA Cardiology</i> , 2018, 3, 375.	3.0	271
61	Factors associated with poor functional outcome in bipolar disorder: sociodemographic, clinical, and neurocognitive variables. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 145-154.	2.2	60
62	Duration of active psychosis and functional outcomes in first-episode non-affective psychosis. <i>European Psychiatry</i> , 2018, 52, 29-37.	0.1	17
63	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989
64	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
65	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
66	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
67	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
68	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
69	Epigenetic outlier profiles in depression: A genome-wide DNA methylation analysis of monozygotic twins. <i>PLoS ONE</i> , 2018, 13, e0207754.	1.1	14
70	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. <i>New England Journal of Medicine</i> , 2018, 379, 2429-2437.	13.9	959
71	Staging, Neurocognition and Social Functioning in Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 709.	1.3	21
72	Global, regional, and national burden of Parkinson's disease, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2018, 17, 939-953.	4.9	1,573

#	ARTICLE	IF	CITATIONS
73	Five Interpersonal Factors Are Predictive of the Response to Treatment of Major Depression With Antidepressants in Primary Care. <i>Frontiers in Psychiatry</i> , 2018, 9, 416.	1.3	12
74	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. <i>JAMA Oncology</i> , 2018, 4, 1553.	3.4	1,260
75	La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016. <i>Medicina Clínica</i> , 2018, 151, 171-190.	0.3	113
76	Global Mortality From Firearms, 1990-2016. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 792.	3.8	189
77	Mapping of global scientific research in comorbidity and multimorbidity: A cross-sectional analysis. <i>PLoS ONE</i> , 2018, 13, e0189091.	1.1	24
78	Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study. <i>European Neuropsychopharmacology</i> , 2017, 27, 350-359.	0.3	26
79	Clinical staging and serum cytokines in bipolar patients during euthymia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 77, 194-201.	2.5	37
80	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015. <i>JAMA Oncology</i> , 2017, 3, 524.	3.4	4,254
81	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1-25.	1.2	2,705
82	Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. <i>Psychopharmacology</i> , 2017, 234, 2563-2570.	1.5	27
83	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. <i>New England Journal of Medicine</i> , 2017, 377, 13-27.	13.9	5,014
84	Child and Adolescent Health From 1990 to 2015. <i>JAMA Pediatrics</i> , 2017, 171, 573.	3.3	306
85	Cancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies. <i>Systematic Reviews</i> , 2017, 6, 69.	2.5	24
86	Manual motor speed dysfunction as a neurocognitive endophenotype in euthymic bipolar disorder patients and their healthy relatives. Evidence from a 5-year follow-up study. <i>Journal of Affective Disorders</i> , 2017, 215, 156-162.	2.0	26
87	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1084-1150.	6.3	573
88	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1151-1210.	6.3	3,565
89	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1211-1259.	6.3	5,578
90	Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet Neurology</i> , The, 2017, 16, 877-897.	4.9	1,521

#	ARTICLE	IF	CITATIONS
91	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , The, 2017, 390, 1423-1459.	6.3	284
92	Global, Regional, and National Levels of Maternal Mortality, 1990–2015: A Systematic Analysis for the Global Burden of Disease Study 2015. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 11-13.	0.2	41
93	A molecular hypothesis to explain direct and inverse co-morbidities between Alzheimer’s Disease, Glioblastoma and Lung cancer. <i>Scientific Reports</i> , 2017, 7, 4474.	1.6	85
94	Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 315-323.	1.8	32
95	High cognitive reserve in bipolar disorders as a moderator of neurocognitive impairment. <i>Journal of Affective Disorders</i> , 2017, 208, 621-627.	2.0	51
96	The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. <i>PLoS ONE</i> , 2017, 12, e0180355.	1.1	218
97	Anorexia nervosa and cancer: a protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , 2017, 6, 137.	2.5	6
98	Risk of mortality among children, adolescents, and adults with autism spectrum disorder or attention deficit hyperactivity disorder and their first-degree relatives: a protocol for a systematic review and meta-analysis of observational studies. <i>Systematic Reviews</i> , 2017, 6, 189.	2.5	11
99	Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. <i>PLoS Medicine</i> , 2016, 13, e1001971.	3.9	75
100	Editorial: Direct and Inverse Comorbidities Between Complex Disorders. <i>Frontiers in Physiology</i> , 2016, 7, 117.	1.3	10
101	Declaración de transparencia: un paso hacia la presentación completa de artículos de investigación. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 63-64.	1.0	13
102	Improving transparency of scientific reporting to increase value and reduce waste in mental health research. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2016, 9, 1-3.	0.2	0
103	Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. <i>Psychological Medicine</i> , 2016, 46, 291-301.	2.7	43
104	Improving transparency of scientific reporting to increase value and reduce waste in mental health research. <i>Revista De Psiquiatría Y Salud Mental</i> , 2016, 9, 1-3.	1.0	12
105	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , the, 2016, 3, e361-e387.	2.1	461
106	The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review. <i>Systematic Reviews</i> , 2016, 5, 6.	2.5	28
107	Diagnosis and neurocognitive profiles in first-episode non-affective psychosis patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 619-628.	1.8	28
108	Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. <i>British Journal of Psychiatry</i> , 2016, 208, 87-93.	1.7	95

#	ARTICLE	IF	CITATIONS
109	Mild cognitive decline. A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA). <i>Maturitas</i> , 2016, 83, 83-93.	1.0	39
110	Rett Syndrome Mutant Neural Cells Lacks MeCP2 Immunoreactive Bands. <i>PLoS ONE</i> , 2016, 11, e0153262.	1.1	2
111	How does family intervention improve the outcome of people with schizophrenia?. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2015, 50, 379-387.	1.6	23
112	Disability in bipolar I disorder: The 36-item World Health Organization Disability Assessment Schedule 2.0. <i>Journal of Affective Disorders</i> , 2015, 174, 353-360.	2.0	35
113	Alzheimer's disease and cancer: the need of putting research into context with previous published systematic reviews. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 569-570.	1.2	4
114	Predictors of functional outcome after a manic episode. <i>Journal of Affective Disorders</i> , 2015, 182, 121-125.	2.0	16
115	The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2015, 4, 19.	2.5	37
116	Suicidal behaviour in first-episode non-affective psychosis: Specific risk periods and stage-related factors. <i>European Neuropsychopharmacology</i> , 2015, 25, 2278-2288.	0.3	58
117	Functional remediation for patients with bipolar II disorder: Improvement of functioning and subsyndromal symptoms. <i>European Neuropsychopharmacology</i> , 2015, 25, 257-264.	0.3	52
118	The prevalence of bipolar disorders in the general population: a growing trending topic?. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 91-92.	0.9	0
119	Alzheimer's Disease and Cancer: Current Epidemiological Evidence for a Mutual Protection. <i>Neuroepidemiology</i> , 2014, 42, 121-122.	1.1	23
120	Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 41-51.	1.0	94
121	Molecular Evidence for the Inverse Comorbidity between Central Nervous System Disorders and Cancers Detected by Transcriptomic Meta-analyses. <i>PLoS Genetics</i> , 2014, 10, e1004173.	1.5	165
122	Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies. <i>Psychotherapy and Psychosomatics</i> , 2014, 83, 89-105.	4.0	164
123	Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. <i>Psychological Medicine</i> , 2014, 44, 37-50.	2.7	37
124	The impact of repeated manic episodes and executive dysfunction on work adjustment in bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 247-254.	1.8	34
125	P.2.d.039 Functional remediation in bipolar II patients: improvement of functioning and subsyndromal symptoms. <i>European Neuropsychopharmacology</i> , 2014, 24, S436-S437.	0.3	4
126	Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. <i>Schizophrenia Research</i> , 2014, 159, 90-94.	1.1	34

#	ARTICLE	IF	CITATIONS
127	Comparing neurocognitive impairment in schizophrenia and bipolar I disorder using the Screen for Cognitive Impairment in Psychiatry Scale. <i>International Journal of Clinical and Health Psychology</i> , 2014, 14, 128-136.	2.7	5
128	The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. <i>BMC Psychiatry</i> , 2013, 13, 127.	1.1	37
129	Psychometric behaviour of the strengths and difficulties questionnaire (SDQ) in the Spanish national health survey 2006. <i>BMC Psychiatry</i> , 2013, 13, 95.	1.1	74
130	The increasing burden of mental and neurological disorders. <i>European Neuropsychopharmacology</i> , 2013, 23, 1337-1339.	0.3	69
131	Course of cognitive deficits in first episode of non-affective psychosis: A 3-year follow-up study. <i>Schizophrenia Research</i> , 2013, 150, 121-128.	1.1	34
132	Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 162-167.	2.5	35
133	Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. <i>Psychiatry Research</i> , 2013, 206, 181-187.	1.7	33
134	Predictors of neurocognitive impairment at 3years after a first episode non-affective psychosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 43, 23-28.	2.5	18
135	The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: A 3 year longitudinal study. <i>Psychiatry Research</i> , 2013, 209, 302-308.	1.7	54
136	Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. <i>Nature Reviews Neuroscience</i> , 2013, 14, 293-304.	4.9	106
137	Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone. <i>Psychopharmacology</i> , 2013, 227, 615-625.	1.5	23
138	The Clinical Implications Of Cognitive Impairment and Allostatic Load in Bipolar Disorder. <i>European Psychiatry</i> , 2013, 28, 21-29.	0.1	119
139	Efficacy of Functional Remediation in Bipolar Disorder: A Multicenter Randomized Controlled Study. <i>American Journal of Psychiatry</i> , 2013, 170, 852-859.	4.0	269
140	Human Adult Periodontal Ligament-Derived Cells Integrate and Differentiate after Implantation into the Adult Mammalian Brain. <i>Cell Transplantation</i> , 2013, 22, 2017-2028.	1.2	51
141	Inverse Comorbidity: The Power of Paradox in the Advancement of Science. <i>Journal of Comorbidity</i> , 2013, 3, 1-3.	3.9	6
142	Neurocognitive Training in Patients with Bipolar Disorders: Current Status and Perspectives. <i>Psychotherapy and Psychosomatics</i> , 2012, 81, 250-252.	4.0	26
143	Neurocognitive Impairment Across the Bipolar Spectrum. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 194-200.	1.9	70
144	Homocysteine and cognition in first-episode psychosis patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 557-564.	1.8	51

#	ARTICLE	IF	CITATIONS
145	Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study. <i>Journal of Psychiatric Research</i> , 2012, 46, 1099-1105.	1.5	118
146	Developmental dynamics of PAFAH1B subunits during mouse brain development. <i>Journal of Comparative Neurology</i> , 2012, 520, 3877-3894.	0.9	10
147	Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 240-247.	1.1	56
148	Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. <i>Schizophrenia Research</i> , 2012, 141, 22-28.	1.1	28
149	Neurocognitive impairment and psychosocial functioning in bipolar II disorder. <i>Acta Psychiatrica Scandinavica</i> , 2012, 125, 309-317.	2.2	78
150	One year longitudinal study of the straight gyrus morphometry in first-episode schizophrenia-spectrum patients. <i>Psychiatry Research - Neuroimaging</i> , 2012, 202, 80-83.	0.9	9
151	Long-Term Outcome of Cognitive Impairment in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e899-e905.	1.1	143
152	Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: A comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP). <i>Schizophrenia Research</i> , 2011, 130, 137-142.	1.1	44
153	Therapeutic use of omega-3 fatty acids in bipolar disorder. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1029-1047.	1.4	87
154	Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. <i>Comprehensive Psychiatry</i> , 2011, 52, 613-622.	1.5	91
155	Straight gyrus morphology in first-episode schizophrenia-spectrum patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 84-90.	2.5	4
156	Sex-specific variation of MRI-based cortical morphometry in adult healthy volunteers: The effect on cognitive functioning. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 616-623.	2.5	19
157	No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. <i>Lancet Oncology</i> , 2011, 12, 604-608.	5.1	122
158	Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features. <i>Psychological Medicine</i> , 2011, 41, 1449-1460.	2.7	72
159	Poor Long-Term Prognosis in Mixed Bipolar Patients. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 671-676.	1.1	59
160	Temporal pole morphology in first-episode schizophrenia patients. <i>Psychiatry Research - Neuroimaging</i> , 2010, 184, 189-191.	0.9	8
161	Neurocognition in bipolar disorders: A closer look at comorbidities and medications. <i>European Journal of Pharmacology</i> , 2010, 626, 87-96.	1.7	105
162	Functional impairment in bipolar II disorder: Is it as disabling as bipolar I?. <i>Journal of Affective Disorders</i> , 2010, 127, 71-76.	2.0	75

#	ARTICLE	IF	CITATIONS
163	The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. <i>BMC Psychiatry</i> , 2010, 10, 47.	1.1	13
164	Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. <i>Annals of General Psychiatry</i> , 2010, 9, .	1.2	1
165	Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). <i>Schizophrenia Research</i> , 2010, 116, 243-251.	1.1	55
166	Longitudinal course of cognition in schizophrenia. <i>British Journal of Psychiatry</i> , 2009, 195, 84-84.	1.7	2
167	Chromosome 8p as a potential hub for developmental neuropsychiatric disorders: implications for schizophrenia, autism and cancer. <i>Molecular Psychiatry</i> , 2009, 14, 563-589.	4.1	211
168	Comparative study of neurocognitive function in euthymic bipolar patients and stabilized schizophrenic patients. <i>Psychiatry Research</i> , 2009, 169, 220-228.	1.7	90
169	Functioning and Disability in Bipolar Disorder: An Extensive Review. <i>Psychotherapy and Psychosomatics</i> , 2009, 78, 285-297.	4.0	348
170	Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 28.	1.0	37
171	The Importance of Negative Comorbidity. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1191-1192.	1.1	7
172	Neurocognitive Dysfunctions in Euthymic Bipolar Patients With and Without Prior History of Alcohol Use. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1120-1127.	1.1	67
173	Treatment Nonadherence and Neurocognitive Impairment in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1017-1023.	1.1	108
174	Motor speed predicts stability of cognitive deficits in both schizophrenic and bipolar I patients at one-year follow-up. <i>European Journal of Psychiatry</i> , 2009, 23, .	0.7	9
175	Neurocognitive endophenotypes (Endophenocognitypes) from studies of relatives of bipolar disorder subjects: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2008, 32, 1426-1438.	2.9	189
176	Functional impairment and previous suicide attempts in bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2008, 20, 300-306.	1.0	14
177	Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. <i>Journal of Affective Disorders</i> , 2008, 109, 286-299.	2.0	256
178	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): Psychometric properties of a brief scale for cognitive evaluation in schizophrenia. <i>Schizophrenia Research</i> , 2008, 99, 139-148.	1.1	78
179	Evidence for association between structural variants in lissencephaly-related genes and executive deficits in schizophrenia or bipolar patients from a Spanish isolate population. <i>Psychiatric Genetics</i> , 2008, 18, 313-317.	0.6	22
180	Neurocognitive Impairment in Bipolar Patients With and Without History of Psychosis. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 233-239.	1.1	142

#	ARTICLE	IF	CITATIONS
181	Neurodevelopmental mechanisms underlying psychosis. <i>International Clinical Psychopharmacology</i> , 2007, 22, S1-S7.	0.9	8
182	Postnatal alterations of the inhibitory synaptic responses recorded from cortical pyramidal neurons in the <i>Lis1/sLis1</i> mutant mouse. <i>Molecular and Cellular Neurosciences</i> , 2007, 35, 220-229.	1.0	16
183	Functional outcome in bipolar disorder: the role of clinical and cognitive factors. <i>Bipolar Disorders</i> , 2007, 9, 103-113.	1.1	497
184	Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 453-460.	2.2	53
185	Bipolar I patients with and without a history of psychotic symptoms: Do they differ in their cognitive functioning?. <i>Journal of Psychiatric Research</i> , 2007, 41, 265-272.	1.5	89
186	Specificity of Cognitive Deficits in Bipolar Disorder versus Schizophrenia. <i>Psychotherapy and Psychosomatics</i> , 2006, 75, 72-84.	4.0	185
187	Variations in genes regulating neuronal migration predict reduced prefrontal cognition in schizophrenia and bipolar subjects from mediterranean Spain: A preliminary study. <i>Neuroscience</i> , 2006, 139, 1289-1300.	1.1	47
188	The high-activity Val allele of the catechol-O-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis. <i>Psychiatric Genetics</i> , 2006, 16, 213-216.	0.6	25
189	Persistent Cognitive Dysfunctions in Bipolar I Disorder and Schizophrenic Patients: A 3-Year Follow-Up Study. <i>Psychotherapy and Psychosomatics</i> , 2005, 74, 113-119.	4.0	143
190	Recall and recognition confabulation in psychotic and bipolar disorders: evidence for two different types without unitary mechanisms. <i>Comprehensive Psychiatry</i> , 2004, 45, 281-288.	1.5	33
191	Specific executive/attentional deficits in patients with schizophrenia or bipolar disorder who have a positive family history of psychosis. <i>Journal of Psychiatric Research</i> , 2003, 37, 479-486.	1.5	47
192	Abnormal motor asymmetry only during bimanual movement in schizophrenic patients compared with healthy subjects. <i>Schizophrenia Research</i> , 2003, 61, 245-253.	1.1	13
193	Miguel de Cervantes, 1547â€“1616. <i>American Journal of Psychiatry</i> , 2001, 158, 1392-1392.	4.0	1
194	Similar effect of family history of psychosis on Sylvian fissure size and auditory P200 amplitude in schizophrenic and bipolar subjects. <i>Psychiatry Research - Neuroimaging</i> , 2001, 108, 29-38.	0.9	16
195	Correlates of Symptom Dimensions in Schizophrenia Obtained with the Spanish Version of the Manchester Scale. <i>Psychopathology</i> , 2000, 33, 259-264.	1.1	19
196	Early age of onset, brain morphological changes and non-consistent motor asymmetry in schizophrenic patients. <i>Schizophrenia Research</i> , 1999, 37, 225-231.	1.1	13